Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, expands the scope of immunogenic compositions in Anixa's breast cancer vaccine development.
The newly allowed patent specifically covers methods of immunizing patients against breast cancer through the administration of an immunogenic composition containing the human α-lactalbumin protein. This protein is typically expressed during lactation in breast tissue and in certain breast cancers, making it a strategic target for immunoprevention approaches.
Anixa Biosciences (NASDAQ: ANIX) ha ricevuto un Avviso di Concessione dall'USPTO per un nuovo brevetto che copre la sua tecnologia per il vaccino contro il cancro al seno. Il brevetto, concesso in licenza esclusiva dalla Cleveland Clinic, amplia l'ambito delle composizioni immunogene nello sviluppo del vaccino contro il cancro al seno di Anixa.
Il brevetto recentemente concesso copre specificamente i metodi di immunizzazione dei pazienti contro il cancro al seno attraverso la somministrazione di una composizione immunogenica contenente la proteina α-lattalbumina umana. Questa proteina è tipicamente espressa durante l'allattamento nei tessuti mammari e in alcuni tipi di cancro al seno, rendendola un obiettivo strategico per approcci di immunoprevenzione.
Anixa Biosciences (NASDAQ: ANIX) ha recibido un Aviso de Concesión de la USPTO para una nueva patente que cubre su tecnología de vacuna contra el cáncer de mama. La patente, licenciada exclusivamente de Cleveland Clinic, amplía el alcance de las composiciones inmunogénicas en el desarrollo de la vacuna contra el cáncer de mama de Anixa.
La nueva patente concedida cubre específicamente los métodos de inmunización de pacientes contra el cáncer de mama a través de la administración de una composición inmunogénica que contiene la proteína α-lactalbumina humana. Esta proteína se expresa típicamente durante la lactancia en el tejido mamario y en ciertos tipos de cáncer de mama, lo que la convierte en un objetivo estratégico para los enfoques de inmunoprevención.
Anixa Biosciences (NASDAQ: ANIX)는 유방암 백신 기술에 대한 새로운 특허에 대해 USPTO로부터 허가 통지를 받았습니다. 이 특허는 Cleveland Clinic으로부터 독점적으로 라이센스가 부여되어 Anixa의 유방암 백신 개발에서 면역원성 조성물의 범위를 확장합니다.
새롭게 허가된 특허는 인간 α-락탈부민 단백질을 포함하는 면역원성 조성물의 투여를 통해 유방암에 대한 환자 면역화 방법을 구체적으로 다룹니다. 이 단백질은 일반적으로 유방 조직에서 수유 중에 발현되며 특정 유방암에서도 발견되어 면역 예방 접근법의 전략적 타겟이 됩니다.
Anixa Biosciences (NASDAQ: ANIX) a reçu un Avis de Concession de l'USPTO pour un nouveau brevet couvrant sa technologie de vaccin contre le cancer du sein. Le brevet, licencié exclusivement par la Cleveland Clinic, élargit le champ des compositions immunogènes dans le développement du vaccin contre le cancer du sein d'Anixa.
Le nouveau brevet accordé couvre spécifiquement les méthodes d'immunisation des patients contre le cancer du sein par l'administration d'une composition immunogène contenant la protéine α-lactalbumine humaine. Cette protéine est généralement exprimée pendant l'allaitement dans le tissu mammaire et dans certains cancers du sein, ce qui en fait une cible stratégique pour les approches d'immunoprévention.
Anixa Biosciences (NASDAQ: ANIX) hat eine Mitteilung über die Genehmigung vom USPTO für ein neues Patent erhalten, das ihre Technologie für einen Impfstoff gegen Brustkrebs abdeckt. Das Patent, das exklusiv von der Cleveland Clinic lizenziert wurde, erweitert den Umfang der immunogenen Zusammensetzungen in der Entwicklung des Brustkrebsimpfstoffs von Anixa.
Das neu genehmigte Patent deckt speziell Methoden zur Immunisierung von Patienten gegen Brustkrebs durch die Verabreichung einer immunogenen Zusammensetzung, die das menschliche α-Lactalbumin-Protein enthält, ab. Dieses Protein wird typischerweise während der Stillzeit im Brustgewebe und bei bestimmten Brustkrebserkrankungen exprimiert, was es zu einem strategischen Ziel für Immunpräventionsansätze macht.
- Patent strengthens intellectual property protection for breast cancer vaccine technology
- Exclusive licensing agreement with Cleveland Clinic secures technology rights
- Expanded patent coverage for immunogenic compositions
- None.
Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach
This newly allowed patent covers methods of immunizing patients against breast cancer by administering an immunogenic composition containing the human α-lactalbumin protein, a protein typically found in breast tissue during lactation but also expressed in certain breast cancers, making it an attractive target for immunoprevention strategies.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "This patent strengthens our intellectual property portfolio and highlights the novelty of our breast cancer vaccine. Our intellectual property portfolio includes multiple issued and pending patents in the
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. These vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-us-patent-and-trademark-office-for-patent-covering-breast-cancer-vaccine-technology-302424026.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the significance of Anixa's (ANIX) new breast cancer vaccine patent?
How does Anixa's (ANIX) breast cancer vaccine technology target cancer cells?
Who owns the intellectual property rights for ANIX's breast cancer vaccine technology?
What is the current patent status of Anixa's (ANIX) breast cancer vaccine?
